Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP),
dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

Enzymes, receptors, and other binding molecules in biological processes can recognize
enantiomers as different molecular entities, due to their different dissociation constants …

The molecular mechanisms underlying major depressive disorder remain poorly
understood, and current antidepressant treatments have many shortcomings. The recent …

Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the
many hypotheses proposed to understand the molecular pathophysiology of depression, it is …

ABSTRACT Introduction: Treatment Resistant Depression (TRD) is a common and
burdensome condition with poor outcomes and few treatment options. Esketamine is the S …

Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-
Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for …

Background Racemic ketamine is a mixture of (R)-ketamine (arketamine) and (S)-ketamine
(esketamine), with the latter regarded as the main isomer for antidepressant effects …

Purpose This study aims to evaluate the effects of the intraoperative application of low-dose
esketamine on postoperative neurocognitive dysfunction (PND) in elderly patients …